Ken Griffin’s Edesa Biotech EDSA Stock Holding History

Ken Griffin’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,630	Closed	-$77.8K	–	13249
2025 Q4	$77.8K	Buy	53,630 +39,598	+282%	+$77.5K	﹤0.01%	11815
2025 Q3	$34.2K	Sell	14,032 -9,482	-40%	-$21.9K	﹤0.01%	12357
2025 Q2	$47.5K	Buy	23,514 +6,923	+42%	+$14.7K	﹤0.01%	11796
2025 Q1	$40.5K	Sell	16,591 -24,353	-59%	-$52.5K	﹤0.01%	12526
2024 Q4	$69.6K	Buy	+40,944	New	+$114K	﹤0.01%	11980
2022 Q1	–	Sell	-2,155	Closed	-$85K	–	13801
2021 Q4	$85K	Buy	+2,155	New	+$103K	﹤0.01%	12872
2018 Q2	–	Sell	-204	Closed	-$49K	–	8912
2018 Q1	$49K	Buy	+204	New	+$50.4K	﹤0.01%	7930

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Ken Griffin's EDSA Position: Q1 2026 in Review

Ken Griffin sold out of Edesa Biotech (EDSA) in Q1 2026, closing a stake of 53,630 shares — an estimated $77.8K sold.

Ken Griffin first reported a position in EDSA in Q1 2018 and held it in 7 quarters. The position peaked at $85K in Q4 2021. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

Ken Griffin reported no remaining Edesa Biotech position as of Q1 2026 after selling out during the quarter.
Ken Griffin sold 53,630 Edesa Biotech shares in Q1 2026, an estimated $77.8K.
Ken Griffin first reported a position in Edesa Biotech in Q1 2018 and held it in 7 quarters.
Ken Griffin's Edesa Biotech position peaked at $85K in Q4 2021.
28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.